Abstract 1877
Background
Based on mRNA expression, accRCC can be divided in four molecular subtypes (ccrcc1-4), associated with prognosis, angiogenic signature, immune phenotype and therapy response. miRNAs are master regulators of mRNA function. We assessed the correlation of miRNA expression with (1) ccrccc1-4 subtypes, (2) mRNA targets and (3) outcome.
Methods
We performed miRNome analysis of 128 accRCC. (1) Unsupervised hierarchical clustering was done using 50 miRNAs with the most variable expression across all samples. Results were validated on TCGA data (n = 255). (2) For miRNAs with subtype-specific expression, we performed pathway analysis of predicted mRNA targets (IPA, KEGG) and assessed target-downregulation in TCGA. (3) We used Cox regression to correlate miRNA expression with overall survival (OS) since diagnosis. Hazard ratios (HR) were correlated with subtype-specific expression (Pearson).
Results
(1) Samples separated in two miRNA clusters, that partially overlapped with molecular subtypes. Cluster 1 consisted of 69% favourable subtypes (ccrcc2 or 3), cluster 2 of 77% unfavourable (ccrcc1 or 4) (p < 2.2e-16). (2) Pathway analysis of predicted mRNA targets and targets suppressed in TCGA, suggested that favourable subtypes exhibit more angiogenic signaling, whereas unfavourable subtypes activate pathways involved in tumor invasiveness. (3) Several miRNAs were significantly associated with OS. There was a robust correlation in the entire dataset between HR for OS and differential expression between favourable/unfavourable subtypes (r = 0.322; p < 0.0001).Table:
973P
miRNA | Subtype-specific expression log2FoldChange <0: higher in ccrcc1 or -4 (unfavourable) log2FoldChange >0: higher in ccrcc2 or -3 (favourable) | *p<0.05 ** false discovery rate <0.05 | Overall survival (hazard ratio) | |
---|---|---|---|---|
182-5p | -1,43 | ** | 1,25 | ** |
3529-3p | -1,42 | ** | 1,37 | ** |
335-3p | -1,33 | ** | 1,25 | ** |
34c-5p | -1,22 | ** | 1,25 | ** |
193b-3p | -1,17 | ** | 1,31 | ** |
370-3p | -1,07 | ** | 1,16 | ** |
199b-5p | -1,05 | ** | 1,26 | ** |
21-3p | -0,89 | ** | 1,47 | ** |
574-5p | -0,89 | ** | 1,40 | ** |
4792 | -0,88 | ** | 0,88 | * |
let-7i-5p | -0,81 | ** | 1,66 | ** |
652-3p | -0,75 | ** | 1,39 | ** |
1301-3p | -0,70 | ** | 1,39 | ** |
222-3p | -0,66 | ** | 1,31 | * |
320a | -0,63 | ** | 1,28 | ** |
425-5p | -0,62 | ** | 1,66 | ** |
149-5p | -0,61 | ** | 1,32 | * |
146b-5p | -0,54 | * | 1,49 | ** |
193b-5p | -0,49 | 1,21 | ** | |
185-5p | -0,49 | ** | 1,42 | ** |
21-5p | -0,42 | * | 1,68 | ** |
7641 | -0,33 | 0,80 | ** | |
320b | -0,28 | 1,25 | ** | |
1260b | -0,15 | 0,79 | ** | |
4454 | 0,15 | 0,80 | ** | |
6880-5p | 0,25 | 0,64 | ** | |
27b-3p | 0,36 | ** | 0,71 | * |
1260a | 0,38 | 0,73 | ** | |
7977 | 0,39 | 0,73 | ** | |
23b-3p | 0,48 | ** | 0,81 | ** |
2392 | 0,55 | 0,80 | ** | |
194-5p | 0,55 | * | 0,74 | ** |
30c-5p | 0,70 | ** | 0,78 | * |
190a-5p | 0,86 | ** | 0,83 | ** |
204-5p | 1,23 | ** | 0,71 | ** |
135a-5p | 1,37 | ** | 0,86 | ** |
Conclusions
accRCC molecular subtypes exhibit different miRNA expression patterns. Differentially expressed miRNAs are implicated in pathways driving tumor biology and strongly correlated with OS. These findings underscore the robustness of the molecular subtypes and are, to the best of our knowledge, the first to show an association of global miRNome expression with outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fonds Wetenschappelijk Onderzoek Vlaanderen.
Disclosure
M. Albersen: Research grant / Funding (self): Ipsen. B. Beuselinck: Advisory / Consultancy, Research grant / Funding (self): Bristol Meyers Squibb; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract